This CME program is derived from content presented from the Congress of Clinical Rheumatology 2020 East and West Virtual Meetings. The expert faculty will first discuss prognosis and diagnosis in systemic sclerosis interstitial lung disease (SSc-ILD), including current prevalence and survival data. Following, Dr. Daniel Furst will analyze both established and emerging therapies for the treatment of SSc-ILD, highlighting the clinical implications of recent trial data. Upon conclusion of this CME activity, learners will be equipped with current information for comprehensively treating and managing patients with systemic sclerosis interstitial lung disease in practice.
Rheumatologists, primary care physicians, PAs, NPs, nurses, pharmacists, and other patient care professionals involved in the management of patients with SSc-ILD
I. Understanding Clinical Presentations of SSc-ILD & Ways to Monitor Lung Function
II. Updates in Treatment Guidelines and Clinical Trial Data of Therapeutic Agents to Slow Lung Function Decline
III. Developing Treatment Plans for Patients: Shared-Decision Making & The Role of the Interprofessional Team
- Understand the clinical presentations of SSc-ILD and ways to observe lung function in patients
- Examine updates in treatment guidelines for patients with SSc-ILD, as well as recent clinical trial data of therapeutic agents used to slow the rate of lung function decline
- Recognize the importance of shared decision-making and the role of the interprofessional team in the development of treatment plans for patients with SSc-ILD
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Alan L. Epstein, MD||Speaker’s Bureau: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Global Services, LLC; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi Genzyme; Sandoz International GmbH; Quest|
|Daniel E. Furst, MD||Consultant/Advisor: Actelion Pharmaceuticals Ltd.; Amgen Inc.; Bristol-Myers Squibb Company; Corbus Pharmaceuticals; Galapagos NV; Genentech Inc.; GlaxoSmithKline; National Institutes of Health; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi; Roche
Research/Grant Support: Actelion Pharmaceuticals Ltd.; Amgen Inc.; Bristol-Myers Squibb Company; Corbus Pharmaceuticals; Galapagos NV; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 Credit TM.
This activity has been supported by an independent educational grant from Boehringer Ingelheim.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Boehringer Ingelheim do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].